Prvulovich E M, Stein R C, Bomanji J B, Ledermann J A, Taylor I, Ell P J
Meyerstein Institute of Oncology, and Department of Surgery, University College London Medical School, United Kingdom.
J Nucl Med. 1998 Oct;39(10):1743-5.
Iodine-13I-metaiodobenzylguanidine (MIBG) is highly concentrated by >60% of carcinoid metastases and thus provides a therapeutic opportunity.
A symptomatic patient with carcinoid liver metastases, unresponsive to chemotherapy combined with interferon-alpha, was subsequently treated with 131I-MIBG.
Radionuclide therapy, which was without significant side effects, resulted in symptomatic improvement and reduced urinary 5-hydroxyindoleacetic acid levels. No new metastases were observed for 15 mo after 131I-MIBG therapy. Gross cystic change occurred in existing liver metastases, presumably as a result of ischemic necrosis. Surgical deroofing and aspiration of cysts led to regeneration of normal liver tissue.
Iodine-131-MIBG therapy can provide prolonged symptomatic relief and improved quality of life in patients with metastatic carcinoid disease unresponsive to other therapies. The antitumor effect of 131I-MIBG was accompanied by few side effects, suggesting that this therapy should be considered in symptomatic patients with an early stage of disease.
碘-131-间碘苄胍（MIBG）在超过60%的类癌转移灶中高度浓聚，因此提供了一种治疗机会。
一名有症状的类癌肝转移患者，对化疗联合α干扰素无反应，随后接受了131I-MIBG治疗。
放射性核素治疗无明显副作用，症状改善，尿5-羟吲哚乙酸水平降低。131I-MIBG治疗后15个月未观察到新的转移灶。现有肝转移灶出现明显的囊性改变，推测是缺血性坏死所致。手术切除囊肿顶部并抽吸囊肿导致正常肝组织再生。
碘-131-MIBG治疗可使转移性类癌病患者在对其他治疗无反应时获得长期的症状缓解并改善生活质量。131I-MIBG的抗肿瘤作用副作用较少，提示对于疾病早期有症状的患者应考虑这种治疗方法。
